Evolving First-Line Treatment Strategies in ERBB2-Positive Metastatic Breast Cancer: A Review.
Importance The treatment landscape of ERBB2 (formerly HER2)-positive metastatic breast cancer has evolved substantially during the past decade, with emerging therapies challenging the long-standing induction-maintenance paradigm established by the CLEOPATRA trial (NCT00567190). However, optimal treatment selection, seq...